ReviewVaccine2019
The rotavirus vaccine development pipeline.
Review in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- T-Cell Responses after Rotavirus Infection or Vaccination in Children: A Systematic Review.Viruses · 2022Pooled it
- Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials.The Lancet. Infectious diseases · 2019Pooled it
- Global rotavirus vaccine introductions and coverage: 2006 - 2016.Human vaccines & immunotherapeutics · 2018Pooled it
- Trial
- Trial
- Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine.Human vaccines & immunotherapeutics · 2018Trial
- Review
- Rapid development of a robust cultivation process for subunit rotavirus vaccine antigen expression in Escherichia coli with the quality by design approach.Bioprocess and biosystems engineering · 2026Article
- A report for the fifth International Workshop on Rotavirus and Norovirus in China.Human vaccines & immunotherapeutics · 2025Article
- Antiviral Activity of Brazilian Propolis from Stingless Bees Against Rotavirus.Microorganisms · 2025Article
- Immunoinformatics-driven design of a multi-epitope vaccine targeting neonatal rotavirus with focus on outer capsid proteins VP4 and VP7 and non structural proteins NSP2 and NSP5.Scientific reports · 2025Article
- Biotechnological Interventions for the Production of Subunit Vaccines Against Group A Rotavirus.Cell biochemistry and function · 2024Review
- Article
- Article
- The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.Vaccine · 2024Review
- Novel Universal Recombinant Rotavirus A Vaccine Candidate: Evaluation of Immunological Properties.Viruses · 2024Article
- Progress in research and development of preventive vaccines for children in China.Frontiers in pediatrics · 2024Review
- Anti-rotavirus antibody measurement in a rotavirus vaccine trial: Choice of vaccine antigen in immunoassays does matter.Human vaccines & immunotherapeutics · 2023Article
- Article
- Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rotavirus disease is a leading global cause of mortality and morbidity in children under 5years of age. The effectiveness of the two globally used oral rotavirus vaccines quickly became apparent when introduced into both developed and developing countries, with significant reductions in rotavirus-associated mortality and hospitalizations. However, the effectiveness and impact of the vaccines is reduced in developing country settings, where the burden and mortality is highest. New rotavirus vaccines, including live oral rotavirus candidates and non-replicating approaches continue to be developed, with the major aim to improve the global supply of rotavirus vaccines and for local implementation, and to improve vaccine effectiveness in developing settings. This review provides an overview of the new rotavirus vaccines in development by developing country manufacturers and provides a rationale why newer candidates continue to be explored. It describes the new live oral rotavirus vaccine candidates as well as the non-replicating rotavirus vaccines that are furthest along in development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.